BMG Pharma S.R.L Grants The Exclusive Distribution Rights For Gelx® Oral Gel And Gelx® Spray For The Treatment Of Oral Mucositis In Cancer Patients To FERRER INTERNACIONAL S.A.

Download PDF Copy

Jan 19 2015

BMG Pharma S.r.l. (BMG) today is pleased to announce that it has signed an exclusive distribution agreement with FERRER INTERNACIONAL S.A. (Ferrer), granting them the rights to promote, sell and market its own product GelX® for the Middle East, Eastern Europe, Russia and North Africa.

The launch of GelX® will allow patients to receive the best care possible by using our innovative delivery technology to eliminate swallowing issues and discomfort associated with chemotherapy, radiotherapy, and related pharmacologic therapies.

"BMG's team are the inventors and generators of some of the major Rx devices in cancer palliative care and we are sure we are providing the market with a new generation of support for cancer patients," said Marco Mastrodonato, CEO of BMG.

"We are very pleased to be working with BMG on the launch of GelX® in these territories," said Antonio Villaró, COO of Ferrer. "We have been impressed by the innovation and efficacy of the GelX® delivery technology and look forward to providing significant improvements in the ease of use and compliance in patients with oral mucositis."

Source:

BMG Pharma S.r.l.

Posted in: Medical Condition News | Pharmaceutical News

Comments (0)

Download PDF Copy

Suggested Reading

City of Hope launches innovative national clinical trials model to expand access to cancer treatments

IFITM3 found to be critical regulator of immunotherapy sensitivity in small cell lung cancer

Study validates deep learning model for predicting future lung cancer risk in Black population

New tool helps identify risky medications for older cancer patients

Lung tumors rewire immune cells in the bone marrow before they reach cancer sites

Cancer cells found to use ketones as alternate fuel for growth

Many patients undergoing surgery for early-stage cancer continue or start opioid prescriptions

New tool can predict where deadly brain cancer might reappear

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.